Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 500 of 6351
-
Could a fizzy fiber drink soothe the gut woes of Weight-Loss drugs?
Symptom relief CompletedThe main objective of this study is to assess the impact of drinking a prebiotic soda on the gastrointestinal (GI) symptoms associated with the use of GLP-1 receptor agonists compared to usual fluid intake.
Sponsor: Olipop, PBC • Aim: Symptom relief
Last updated Aug 06, 2026 00:00 UTC
-
Could a 3-Week radiation course replace 6 weeks for head and neck cancer?
Disease control Recruiting nowHypo-fractionated radiotherapy reduces the OTT (overall treatment time) which may in turn reduce rapid accelerated repopulation of clonogenic cells during waiting period after surgery. If this holds true, there is a potential to achieve better loco-regional control in with PORT f…
Phase 2/3 • Sponsor: All India Institute of Medical Sciences • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
Magnetic brain zaps may restore movement after stroke
Disease control By invitation onlyStroke is a leading cause of disability with many patients suffering chronic motor function impairments that affect their day-to-day activities. The goal of this proposal is to provide a first assessment of the feasibility and efficacy of an innovative non-invasive brain stimulat…
Sponsor: Magnetic Tides • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
Immune cells engineered to hunt viruses show promise for transplant kids
Disease control Recruiting nowThe goal of this prospective clinical study is to evaluate the safety and efficacy of Multi-Virus Specific T cells (LB-DTK-MV) in pediatric patients with systemic viral infection, including CMV, EBV, and BKV, after allogeneic hematopoietic stem cell transplantation (allo-HSCT). T…
Sponsor: LucasBio • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
Brain aneurysm showdown: which procedure is safer?
Disease control Recruiting nowBrief Summary: The goal of this clinical trial is to compare whether the traditional approach (stent-assisted coiling) is associated with a lower complication rate than flow diverter (Pipeline™) treatment for unruptured intracranial wide-neck bifurcation aneurysms. It will also …
Sponsor: Nanfang Hospital, Southern Medical University • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
Experimental biologic aims to eliminate persistent HPV16 infection
Disease control Recruiting nowThis is a randomized, double-blind, placebo controlled study to determine the efficacy and safety of NWRD09 in adult women with persistent cervical HPV16 infection.
Sponsor: Newish Biotech (Wuxi) Co., Ltd. • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
Immunotherapy cocktail takes on tough throat cancer
Disease control Recruiting nowIn this study, the investigators designed a randomized, open-label, phase II clinical trial for high-risk locally advanced nasopharyngeal carcinoma (T4 or N3 or EBV DNA ≥1500 copies/ml, AJCC 9th edition) that is sensitive to chemotherapy and PD-1 monoclonal antibody therapy. The …
Phase 2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New hope for Hard-to-Treat breast cancer: targeted combo enters final testing
Disease control Not yet recruitingNTQ1062-301 is a randomized, double-blind, placebo-controlled Phase III clinical trial to evaluate the efficacy and safety of the small-molecule AKT inhibitor NTQ1062 combined with fulvestrant versus placebo combined with fulvestrant in patients with HR positive, HER2 negative, l…
Phase 3 • Sponsor: Nanjing Chia-tai Tianqing Pharmaceutical • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
New drug combo shows promise for Hard-to-Treat lung cancer
Disease control Not yet recruitingBefotertinib is a third-generation EGFR-TKI independently developed in China. In first-line treatment of advanced non-small cell lung cancer (NSCLC) with EGFR mutations, it has demonstrated a median progression-free survival (PFS) of 22.1 months, representing the longest reported…
Phase 2 • Sponsor: Hebei Medical University Fourth Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
New drug combo shows promise for Hard-to-Treat breast cancer
Disease control Not yet recruitingThis study is an open-label, prospective, phase 2, randomized controlled study to evaluate the efficacy and safety of apolitovorrelizumab (QL1706) in combination with platinum chemotherapy versus platinum chemotherapy in the treatment of advanced unresectable and or metastatic tr…
Phase 2 • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
Lab-Grown eye cells implanted to fight blindness
Disease control Not yet recruitingPhase I Study of the Safety and Preliminary Efficacy of Human induced pluripotent stem cells-derived Retinal Pigment Epithelial (HiPSC-RPE) Cells Subretinal Transplantation in Late-Stage Age-Related Macular Degeneration(AMD) Patients
Phase 1/2 • Sponsor: The First Affiliated Hospital with Nanjing Medical University • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
Triple-Drug attack aims to beat rare lymphoma
Disease control Not yet recruitingExtranodal natural killer/T-cell lymphoma (ENKTL) is an aggressive non-Hodgkin lymphoma with poor prognosis in advanced stages, with a 5-year overall survival (OS) rate of less than 30% despite asparaginase-based regimens. Preclinical and clinical evidence suggests that PD-L1 is …
Phase 2 • Sponsor: LIANG WANG • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Gut bacteria boost? new trial combines probiotic with cancer therapy for rectal tumors
Disease control Recruiting nowThis prospective, single-center, randomized controlled trial aims to assessing the efficacy and safety of neoadjuvant chemoradiation plus Tislelizumab (PD-1 inhibitor) with or without Probio-M9 and subsequent TME surgery, by comparing assorted endpoints between two experiment gro…
Phase 2 • Sponsor: Seventh Medical Center of PLA General Hospital • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New hope for hard-to-treat nose and throat cancer: targeted drug combo shows promise
Disease control Recruiting nowBased on the short-term efficacy and plasma EBV DNA levels following immuno-induction chemotherapy, patients with locally advanced nasopharyngeal carcinoma who derive different benefits from this treatment can be identified. For high-risk patients who do not respond to immuno-ind…
Phase 2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
Home eye tests could save thousands from blindness
Diagnosis Recruiting nowThe vast majority of glaucoma cases in the United States go undetected and untreated until the late stages of the disease. Open-angle glaucoma is a progressive condition that is asymptomatic in its early to moderate stages and may be amenable to screening through telemedicine-bas…
Sponsor: University of California, San Francisco • Aim: Diagnosis
Last updated Jun 27, 2026 12:07 UTC
-
Gout drug pegloticase gets a shot in the arm: new subcutaneous option tested
Disease control Recruiting nowThe primary objective of this trial is to evaluate the effect of pegloticase 18 mg subcutaneously (SC) every two weeks with methotrexate (MTX) versus pegloticase 8 mg intravenously (IV) every two weeks with MTX on the response rate during Month 6, as measured by the sustained nor…
Phase 3 • Sponsor: Amgen • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
New hope for lupus patients: drug trial targets kidney damage
Disease control Recruiting nowThe goal of this clinical trial is to learn if cenerimod, on top of regular treatment, works to treat active lupus nephritis in adults with systemic lupus erythematosus and active lupus nephritis. It will also learn about the safety of cenerimod. The main questions it aims to ans…
Phase 3 • Sponsor: Viatris Innovation GmbH • Aim: Disease control
Last updated Aug 01, 2026 00:00 UTC
-
Electric suit may help people with spinal cord injury walk better
Disease control By invitation onlySpinal cord injuries (SCI) impair neural communication, leading to difficulties in walking due to muscle weakness, altered reflexes, and impaired muscle activation below the injury. Functional electrical stimulation (FES) has been shown to enhance voluntary control, strength, and…
Sponsor: Stichting Reade • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New cocktail of drugs shows promise for Tough-to-Treat throat cancer
Disease control Recruiting nowThis is a single-center, prospective, single-arm, phase II clinical study, to evaluate the therapeutic efficacy and safety of envafolimab combined with chemoradiotherapy and recombinant human endostatin in patients with locally advanced nasopharyngeal carcinoma.
Phase 2 • Sponsor: Chongqing University Cancer Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
New device aims to fix lingering aortic tears after emergency surgery
Disease control Not yet recruitingThis is a prospective, multicenter, randomized controlled clinical study. A total of 198 eligible subjects will be enrolled and randomly assigned in a 1:1 ratio to either the Study Group or the Control Group. Subjects in the Study Group will receive surgical treatment using the s…
Sponsor: West China Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC